Last updated: September 5, 2026
TENEX is the former U.S. brand name for immediate-release guanfacine hydrochloride, an alpha-2A adrenergic receptor agonist approved for hypertension. Its commercial position has largely disappeared as a branded product. The active ingredient remains available through generic guanfacine tablets, while the higher-value ADHD market shifted toward extended-release guanfacine, marketed originally as INTUNIV.
TENEX has no meaningful remaining brand moat in the United States. Its market is defined by low-cost generic supply, limited pricing power, off-label ADHD use, and substitution by extended-release products when once-daily ADHD treatment is required.
What is TENEX and how is it used?
TENEX contains immediate-release guanfacine hydrochloride. The FDA approved it for the treatment of hypertension, either alone or with other antihypertensive drugs. The product reduces sympathetic nerve impulses and lowers blood pressure through central alpha-2 adrenergic activity (U.S. Food and Drug Administration [FDA], 2013).
| Attribute |
TENEX |
| Active ingredient |
Guanfacine hydrochloride |
| Formulation |
Immediate-release tablet |
| Historical strengths |
1 mg and 2 mg tablets |
| Original indication |
Hypertension |
| U.S. brand status |
No meaningful current commercial presence |
| Current supply |
Generic guanfacine immediate-release tablets |
| Main commercial successor |
INTUNIV, extended-release guanfacine |
| Regulatory pathway |
Abbreviated New Drug Application, or ANDA, for generics |
| Current market role |
Generic hypertension therapy and off-label ADHD treatment |
Immediate-release guanfacine is also used off label for ADHD, tic disorders, sleep disturbance associated with stimulant therapy, and behavioral symptoms. These uses are clinically relevant but do not create branded exclusivity for TENEX.
When did TENEX lose exclusivity?
TENEX lost practical market exclusivity after the expiration of its original product and formulation protection, allowing generic manufacturers to enter. The product’s commercial decline accelerated as guanfacine became available through multiple generic suppliers.
The original TENEX approval dates to the 1980s. Any original patent rights associated with the immediate-release product have expired. No commercially meaningful patent protection remains for the basic immediate-release guanfacine tablet in the United States.
TENEX exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| Original FDA approval |
1980s |
Established guanfacine as an antihypertensive |
| Generic entry |
After expiration of original protection |
Reduced branded pricing power |
| Brand erosion |
1990s-2000s |
Prescriptions migrated to generic guanfacine |
| INTUNIV approval |
2009 |
Created a separate extended-release ADHD product |
| Generic ER guanfacine entry |
After expiration of relevant ER protections |
Increased substitution pressure in ADHD |
| Current position |
2020s |
Generic immediate-release market with limited brand value |
The exact date of the last commercial TENEX shipment is less important than the present legal position: the immediate-release product is exposed to generic competition, and the brand has no material regulatory exclusivity comparable with a newly launched prescription product.
What is the Orange Book status of TENEX?
The FDA Orange Book is relevant to TENEX mainly as evidence that no active brand-listed patent barrier supports continued exclusivity for the immediate-release product. The Orange Book lists approved drug products and patent information submitted by sponsors, but a historical brand can remain commercially obsolete even after its regulatory listing persists.
The relevant distinction is between:
- The original immediate-release TENEX product.
- Generic immediate-release guanfacine tablets.
- INTUNIV extended-release guanfacine.
- Generic extended-release guanfacine tablets.
These products have different regulatory records and, historically, different patent positions.
Current regulatory position
Generic guanfacine immediate-release tablets are approved through ANDAs. Generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. They do not need to repeat the original clinical efficacy program required for the innovator application.
The FDA-approved immediate-release product is not protected by current new chemical entity exclusivity, pediatric exclusivity, or orphan-drug exclusivity. The hypertension indication is mature and broadly substitutable.
What patents protect TENEX?
No active U.S. patent estate appears to provide commercially meaningful protection for the basic TENEX immediate-release tablet.
| Patent category |
TENEX position |
| Active ingredient patent |
Expired |
| Immediate-release tablet patent |
Expired or commercially irrelevant |
| Method-of-use patent for hypertension |
No meaningful current exclusivity |
| Pediatric exclusivity |
Expired |
| New chemical entity exclusivity |
Expired |
| Formulation patent |
No material active barrier identified for the immediate-release product |
| Manufacturing patent |
No known barrier that prevents generic supply |
| Orange Book blocking patent |
None of practical commercial significance |
How does TENEX compare with INTUNIV patents?
INTUNIV is an extended-release guanfacine product and should not be treated as the same patent asset as TENEX. Extended-release products can obtain protection through drug-delivery technology, release-control formulations, and method-of-use claims even when the active ingredient is old.
The commercial value of INTUNIV protection historically came from the formulation and ADHD indication, not from guanfacine itself. Once those protections expired or became vulnerable to generic challenges, generic extended-release guanfacine entered the market.
| Issue |
TENEX |
INTUNIV |
| Dosage form |
Immediate-release tablet |
Extended-release tablet |
| Primary historical indication |
Hypertension |
ADHD |
| Active ingredient |
Guanfacine |
Guanfacine |
| Core patent issue |
Old molecule and conventional tablet |
Controlled-release formulation and use |
| Generic substitution |
Broad and mature |
Increasing after ER generic entry |
| Current pricing power |
Very limited |
Historically higher, now reduced |
How many patents cover TENEX?
For practical market analysis, zero active U.S. patents should be assumed to block generic immediate-release guanfacine tablets.
Historical patent counts can be misleading because a patent may appear in older regulatory records while having expired, been disclaimed, or ceased to affect generic entry. The relevant question is whether a live, enforceable patent can support an injunction or delay an ANDA launch. For TENEX, the answer is no on the available public record.
This position also means that the main barriers are operational rather than legal:
- FDA approval and manufacturing compliance.
- Reliable supply of guanfacine hydrochloride active pharmaceutical ingredient.
- Quality control for low-volume strengths.
- Distribution economics.
- Pharmacy contracting and wholesaler access.
Which companies are challenging TENEX exclusivity?
No current branded challenger is required to challenge TENEX. Generic entry has already established a competitive market.
Companies that have historically supplied guanfacine tablets or related products have included large generic manufacturers and specialty suppliers. Supplier participation can change because of discontinuations, portfolio rationalization, manufacturing transfers, and FDA compliance actions. The market does not depend on one exclusive generic manufacturer.
The competitive model is therefore different from a typical Paragraph IV launch against a protected blockbuster. Generic manufacturers compete through ANDA approval, price, availability, and channel coverage rather than through a high-value patent litigation campaign.
Are there Paragraph IV challenges involving TENEX?
No material current Paragraph IV dispute is publicly associated with the basic immediate-release TENEX product. Paragraph IV litigation is more relevant to protected formulations such as extended-release guanfacine products.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. For immediate-release guanfacine, the absence of a meaningful active patent estate removes the primary basis for a new patent challenge.
The commercial implication is straightforward: immediate-release generic manufacturers can compete without waiting for a future patent cliff.
What formulations are protected by guanfacine patents?
The principal formulation distinction is between immediate-release and extended-release guanfacine.
Immediate-release guanfacine
Immediate-release guanfacine is a conventional tablet. It is inexpensive to manufacture and is not differentiated by a complex delivery system. Its clinical use can be limited by sedation, fatigue, hypotension, and the need for dosing adjustments.
Extended-release guanfacine
Extended-release guanfacine was developed to provide once-daily administration and a different exposure profile. INTUNIV was approved for ADHD in children and adolescents. Its formulation and labeled use supported a higher price than generic immediate-release guanfacine.
The extended-release product created the principal branded value in guanfacine. That value was separate from TENEX and depended on maintaining a formulation-based commercial advantage.
What is the FDA regulatory status of TENEX?
The FDA regulatory status is mature and genericized.
The immediate-release product has no current new-drug exclusivity. Generic guanfacine tablets are available through ANDAs, subject to FDA quality, bioequivalence, labeling, and manufacturing requirements. The product is not a biologic and does not face biosimilar competition.
Is there biosimilar risk for TENEX?
No. Biosimilars apply to biological products. Guanfacine is a small-molecule chemical drug, so the relevant competitive pathway is generic substitution rather than biosimilar interchangeability.
The more important regulatory distinction is between:
- ANDA approval for immediate-release guanfacine.
- ANDA approval for extended-release guanfacine.
- Any state-level substitution rules governing the pharmacy transaction.
What is the financial trajectory of TENEX?
TENEX’s branded financial trajectory is effectively a decline from a branded antihypertensive product to a low-value generic market. Public companies do not generally report standalone revenue for generic guanfacine immediate-release tablets, and no reliable current TENEX brand revenue series is publicly disclosed.
| Period |
Financial position |
| Pre-generic period |
Branded prescription revenue and normal antihypertensive pricing |
| Early generic period |
Rapid price erosion and volume migration |
| Mature generic period |
Low unit prices, fragmented supplier revenue |
| Current period |
Limited or negligible branded revenue; generic market economics |
The product’s revenue erosion followed the standard small-molecule generic pattern:
- Generic entry reduced price.
- Pharmacy substitution shifted volume away from the brand.
- Multiple suppliers compressed margins.
- The branded product lost promotional support.
- Manufacturing became a portfolio decision rather than a strategic growth asset.
What drives current guanfacine revenue?
Current revenue is determined by generic prescription volume and the number of active suppliers. The main demand drivers are:
- Continued use in hypertension, although guanfacine is not a leading first-line antihypertensive.
- Off-label ADHD prescribing.
- Use in patients who do not tolerate stimulants.
- Use in combination with stimulant therapy.
- Pediatric and adolescent behavioral-treatment demand.
- Availability of low-cost immediate-release tablets.
The principal revenue constraints are stronger:
- Generic price competition.
- Limited branded differentiation.
- Substitution by other antihypertensives.
- Prescriber preference for approved extended-release ADHD treatment.
- Low manufacturer willingness to promote an old molecule.
- Potential supply volatility in a small market.
How does TENEX compare with competing ADHD drugs?
TENEX competes indirectly in ADHD because immediate-release guanfacine is generally used off label. The main direct branded comparator was INTUNIV, while the broader market includes stimulant and nonstimulant therapies.
| Product class |
Example |
Regulatory status for ADHD |
Commercial position |
| Immediate-release guanfacine |
Generic guanfacine tablets |
Off label |
Low-cost, flexible dosing |
| Extended-release guanfacine |
INTUNIV and generics |
FDA approved |
Once-daily nonstimulant option |
| Stimulants |
Methylphenidate, amphetamine products |
FDA approved |
Largest established segment |
| Nonstimulants |
Atomoxetine, viloxazine |
FDA approved |
Alternative branded and generic options |
| Alpha-2 agonists |
Guanfacine, clonidine |
Varies by formulation |
Sedation and blood-pressure effects affect use |
TENEX can be attractive where cost and flexible titration matter. It is less competitive where once-daily dosing, FDA-approved ADHD labeling, or smoother pharmacokinetics are important.
What generic launch risks exist for TENEX?
Generic launch risk is low because the product is already genericized and lacks a material patent barrier. The risks are operational rather than litigation-driven.
Supply and manufacturing risks
Small generic markets can experience disruptions when manufacturers discontinue low-margin products. Relevant risks include:
- Active pharmaceutical ingredient shortages.
- Limited manufacturing slots.
- Product recalls.
- FDA warning letters or import alerts.
- Discontinuation of one tablet strength.
- Wholesaler delisting.
- Concentration among a small number of suppliers.
Manufacturing IP is unlikely to prevent market participation, but manufacturing economics can reduce the number of active suppliers.
Pricing risk
Guanfacine immediate-release pricing is exposed to commodity-style generic competition. Additional entrants generally reduce average selling prices, although a shortage or supplier exit can create temporary price increases.
What litigation affects TENEX?
No material current patent litigation affecting immediate-release TENEX is publicly established. Historical disputes involving guanfacine extended-release products should be analyzed separately because they concern different formulations, indications, and patent claims.
The litigation exposure for a company supplying immediate-release guanfacine is more likely to arise from:
- Product liability.
- Manufacturing defects.
- False advertising.
- Distribution contracts.
- Regulatory compliance.
- Antitrust issues in generic contracting.
Patent-infringement risk is comparatively low for the conventional immediate-release product.
Are there licensing deals involving TENEX?
No major active licensing transaction appears to support a current TENEX commercial franchise. The historical value in guanfacine licensing was associated more with extended-release development and ADHD commercialization than with the mature immediate-release antihypertensive product.
A company evaluating a guanfacine opportunity would generally pursue:
- A low-cost generic supply arrangement.
- An ANDA acquisition.
- A manufacturing or distribution agreement.
- An extended-release formulation asset.
- A combination product or specialty indication.
A license covering the old TENEX immediate-release brand alone would have limited strategic value unless it included manufacturing rights, distribution infrastructure, or a differentiated new formulation.
What is the geographic coverage of TENEX?
The strongest commercial relevance is in the United States, where the drug has a long FDA history and generic substitution infrastructure. Guanfacine is also marketed internationally under different brand names and generic labels, but regulatory approvals, strengths, indications, and commercial status vary by country.
Geographic value is limited by the age of the molecule and the availability of local generic competitors. The most defensible commercial assets are therefore not territorial patent rights but regulatory registrations, supply reliability, and market access.
How strong is the TENEX patent estate?
The TENEX patent estate is weak to nonexistent as a current commercial defense.
| Patent-strength factor |
Assessment |
| Remaining composition-of-matter protection |
None |
| Immediate-release formulation protection |
None of material significance |
| Method-of-use exclusivity |
None of material significance |
| Orange Book blocking position |
Weak |
| Generic entry exposure |
High |
| Litigation leverage |
Low |
| Manufacturing differentiation |
Limited |
| Brand pricing power |
Negligible |
The stronger historical IP position belonged to extended-release guanfacine products, not TENEX itself. Even there, formulation patents have expiration dates and can be challenged through ANDA litigation.
Key Takeaways
- TENEX is the former brand for immediate-release guanfacine hydrochloride.
- Its original hypertension market has matured into a low-price generic category.
- No meaningful active U.S. patent or exclusivity barrier protects the conventional immediate-release tablet.
- Current commercial value is concentrated in generic supply, not the TENEX brand.
- INTUNIV and extended-release guanfacine should be analyzed separately because their formulation and ADHD patents created a different commercial profile.
- No material current Paragraph IV or patent litigation is associated with basic immediate-release TENEX.
- Biosimilar risk does not apply because guanfacine is a small-molecule drug.
- Revenue data for TENEX are not publicly reported as a standalone branded series; any current revenue is likely generic and fragmented.
- The principal risks are supply disruption, low margins, manufacturer exits, and substitution by competing ADHD or antihypertensive therapies.
FAQs
Is TENEX still sold in the United States?
The TENEX brand has little or no meaningful current commercial presence. Generic immediate-release guanfacine tablets remain available through FDA-approved ANDA products.
Can generic guanfacine be used for ADHD?
Immediate-release guanfacine is commonly used off label for ADHD, but the FDA-approved ADHD formulation is extended-release guanfacine.
Is guanfacine a controlled substance?
No. Guanfacine is not federally scheduled as a controlled substance, unlike many stimulant ADHD medicines.
Why is generic guanfacine cheaper than INTUNIV?
Immediate-release guanfacine is an old, conventional tablet with no meaningful exclusivity. INTUNIV was priced as an extended-release ADHD product with formulation and indication differentiation.
Does TENEX have a meaningful acquisition value?
The TENEX brand alone has limited acquisition value. A transaction could become commercially relevant only if it includes an approved ANDA portfolio, reliable manufacturing capacity, distribution rights, or a differentiated extended-release or combination product.
References
-
U.S. Food and Drug Administration. (2013). Tenex (guanfacine hydrochloride) tablets: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
-
U.S. Food and Drug Administration. (2009). Intuniv (guanfacine hydrochloride) extended-release tablets: Prescribing information. FDA.
-
National Library of Medicine. (2024). Guanfacine. DailyMed.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
